Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10973
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tan, Rüyal | - |
dc.contributor.author | Bölükbaşı Hatip, Funda | - |
dc.contributor.author | Açıkalın, Öznur | - |
dc.contributor.author | Yamauchi, A. | - |
dc.contributor.author | Kataoka, Y. | - |
dc.contributor.author | Hatip-Al-Khatib, İzzettin | - |
dc.date.accessioned | 2019-08-16T13:34:12Z | |
dc.date.available | 2019-08-16T13:34:12Z | |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0955-8810 | - |
dc.identifier.uri | https://hdl.handle.net/11499/10973 | - |
dc.identifier.uri | https://doi.org/10.1097/FBP.0000000000000355 | - |
dc.description.abstract | Nicotinic acetylcholine receptors (nAChRs) are implicated in the pathogenesis of Parkinson's disease (PD). Varenicline tartrate is a partial agonist at ?4ß2 and full agonist at ?7 neuronal nAChR subunits. A unilateral lesion of the substantia nigra (SN) has been used as a reliable model of PD. This study aimed to investigate the effect of varenicline on locomotor and nonlocomotor behavioral deficits induced by a unilateral lesion of the SN induced by 6-hydroxydopamine (6-OHDA) (8 g/4 l). Varenicline (1 mg/kg) was administered to the lesioned rats daily for 2 weeks, which commenced 3 weeks after 6-OHDA administration. The results showed that varenicline improved motor deficits induced by 6-OHDA. It improved locomotor and nonlocomotor activities such as forelimb use, rotarod performance, and forelimb asymmetry. Varenicline did not change rearing or vibrissae-elicited forelimb placing but did increase apomorphine-induced rotation. In conclusion, the present results suggest that drugs with specific partial/full agonistic activity on nAChR subunits could be of value in the treatment of neurodegenerative disorders such as PD. © 2018 Wolters Kluwer Health, Inc. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams and Wilkins | en_US |
dc.relation.ispartof | Behavioural Pharmacology | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | 6-hydroxydopamine | en_US |
dc.subject | behavioral deficits | en_US |
dc.subject | Parkinson's disease | en_US |
dc.subject | rat | en_US |
dc.subject | substantia nigra | en_US |
dc.subject | varenicline | en_US |
dc.subject | oxidopamine | en_US |
dc.subject | apomorphine | en_US |
dc.subject | dopamine | en_US |
dc.subject | nicotinic agent | en_US |
dc.subject | nicotinic receptor | en_US |
dc.subject | animal behavior | en_US |
dc.subject | animal experiment | en_US |
dc.subject | animal model | en_US |
dc.subject | apomorphine test | en_US |
dc.subject | Article | en_US |
dc.subject | behavior disorder | en_US |
dc.subject | brain asymmetry | en_US |
dc.subject | comparative study | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug effect | en_US |
dc.subject | experimental parkinsonism | en_US |
dc.subject | forelimb | en_US |
dc.subject | forelimb asymmetry | en_US |
dc.subject | locomotion | en_US |
dc.subject | male | en_US |
dc.subject | motor dysfunction | en_US |
dc.subject | nonhuman | en_US |
dc.subject | psychopharmacotherapy | en_US |
dc.subject | rearing | en_US |
dc.subject | reinforcement | en_US |
dc.subject | rotarod test | en_US |
dc.subject | treatment duration | en_US |
dc.subject | vibrissae elicited forelimb placing | en_US |
dc.subject | animal | en_US |
dc.subject | corpus striatum | en_US |
dc.subject | disease model | en_US |
dc.subject | injuries | en_US |
dc.subject | metabolism | en_US |
dc.subject | motor activity | en_US |
dc.subject | Parkinson disease | en_US |
dc.subject | physiology | en_US |
dc.subject | Sprague Dawley rat | en_US |
dc.subject | Animals | en_US |
dc.subject | Apomorphine | en_US |
dc.subject | Behavior, Animal | en_US |
dc.subject | Corpus Striatum | en_US |
dc.subject | Disease Models, Animal | en_US |
dc.subject | Dopamine | en_US |
dc.subject | Male | en_US |
dc.subject | Motor Activity | en_US |
dc.subject | Nicotinic Agonists | en_US |
dc.subject | Oxidopamine | en_US |
dc.subject | Parkinson Disease | en_US |
dc.subject | Rats | en_US |
dc.subject | Rats, Sprague-Dawley | en_US |
dc.subject | Receptors, Nicotinic | en_US |
dc.subject | Substantia Nigra | en_US |
dc.subject | Varenicline | en_US |
dc.title | Effect of varenicline on behavioral deficits in a rat model of Parkinson's disease induced by unilateral 6-hydroxydopamine lesion of substantia nigra | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 327 | |
dc.identifier.startpage | 327 | en_US |
dc.identifier.endpage | 335 | en_US |
dc.identifier.doi | 10.1097/FBP.0000000000000355 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 29064842 | en_US |
dc.identifier.scopus | 2-s2.0-85048625643 | en_US |
dc.identifier.wos | WOS:000435106900004 | en_US |
dc.identifier.scopusquality | Q2 | - |
dc.owner | Pamukkale University | - |
item.openairetype | Article | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
3
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
3
checked on Nov 22, 2024
Page view(s)
32
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.